Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 9.41%7.21B | 11.66%1.98B | 12.24%1.79B | 9.28%1.82B | 8.71%6.59B | 3.32%1.77B | 3.66%1.6B | 7.81%1.66B | 22.92%6.06B | 1.71B |
Operating revenue | 9.62%7B | 12.80%1.77B | 12.24%1.79B | 9.28%1.82B | 9.89%6.39B | 7.08%1.57B | 3.66%1.6B | 7.81%1.66B | 17.85%5.81B | --1.46B |
Cost of revenue | 7.53%4.42B | 12.20%1.21B | 10.41%1.07B | 8.68%1.15B | 6.71%4.11B | -4.74%1.08B | -1.59%965.65M | 9.41%1.06B | 29.62%3.85B | 1.13B |
Gross profit | 12.52%2.79B | 10.81%766.49M | 15.02%726.76M | 10.33%670.44M | 12.19%2.48B | 19.00%691.72M | 12.85%631.83M | 5.14%607.66M | 12.79%2.21B | 581.29M |
Operating expense | -7.12%1.64B | -17.34%384.48M | 8.14%407.3M | 6.87%418.03M | 15.00%1.76B | 6.12%465.16M | 1.32%376.65M | -0.38%391.17M | 9.62%1.53B | 438.33M |
Selling and administrative expenses | -9.60%1.14B | -36.08%158.2M | 10.54%319.43M | 8.18%327.34M | 14.24%1.27B | 0.16%247.48M | -1.32%288.97M | -1.91%302.57M | 4.36%1.11B | --247.08M |
-General and administrative expense | -9.60%1.14B | ---- | ---- | ---- | 14.24%1.27B | ---- | ---- | ---- | --1.11B | ---- |
Research and development costs | -2.85%384.04M | 1.25%115M | 0.23%87.88M | 2.37%90.7M | 9.45%395.28M | 6.91%113.59M | -6.34%87.68M | 4.07%88.59M | 1.76%361.14M | --106.24M |
Depreciation amortization depletion | 3.87%111.28M | ---- | ---- | ---- | 21.67%107.14M | ---- | ---- | ---- | --88.06M | ---- |
-Depreciation and amortization | 3.87%111.28M | ---- | ---- | ---- | 21.67%107.14M | ---- | ---- | ---- | --88.06M | ---- |
Other operating expenses | ---- | ---- | ---- | ---- | 86.32%-3.04M | ---- | ---- | ---- | -36.39%-22.24M | ---3.05M |
Operating profit | 60.76%1.16B | 68.62%382.01M | 25.18%319.45M | 16.59%252.41M | 5.84%718.58M | 58.48%226.56M | 35.66%255.18M | 16.85%216.5M | 20.70%678.96M | 142.96M |
Net non-operating interest income expense | -25.32%-701.12M | 14.86%-114.42M | -30.93%-197.61M | -69.11%-221.4M | -20.92%-559.45M | 9.85%-134.39M | -31.44%-150.94M | -9.67%-130.92M | -80.62%-462.67M | -149.08M |
Non-operating interest income | -28.84%44.42M | ---- | ---- | 21.47%14.05M | 84.38%62.43M | ---- | ---- | --11.57M | 193.13%33.86M | ---- |
Non-operating interest expense | 16.76%602.57M | -82.56%15.87M | 30.93%197.61M | 58.81%202.51M | 16.09%516.06M | -30.51%91.01M | 31.44%150.94M | 6.82%127.52M | 90.13%444.54M | --130.96M |
Total other finance cost | 35.12%142.98M | ---- | ---- | 119.99%32.94M | 103.57%105.82M | ---- | ---- | --14.97M | 53.39%51.98M | ---- |
Other net income (expense) | -121.07%-10.09M | -514.28%-57.05M | 48.08%-2.42M | 854.79%35.97M | -60.65%47.89M | -53.72%13.77M | -135.28%-4.66M | -95.28%3.77M | 176.04%121.72M | 29.76M |
Gain on sale of security | -153.33%-37.81M | ---- | ---- | -32.98%-2.65M | -175.68%-14.93M | ---- | ---- | ---2M | 273.69%19.72M | ---- |
Earnings from equity interest | -41.41%36.8M | -135.39%-10.16M | -132.47%-2.42M | 285.03%47.05M | -38.41%62.82M | 186.09%28.7M | -43.58%7.45M | -84.69%12.22M | 55.14%102M | --10.03M |
Special income (charges) | ---9.08M | ---- | ---- | -30.58%-8.43M | --0 | ---- | ---12.12M | ---6.46M | --0 | ---- |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | --12.12M | ---- | ---- | ---- |
-Write off | --9.08M | ---- | ---- | ---- | --0 | ---- | ---- | ---- | --0 | ---- |
-Gain on sale of property,plant,equipment | ---- | ---- | ---- | -30.58%-8.43M | ---- | ---- | ---- | ---6.46M | ---- | ---- |
Income before tax | 114.47%444M | 98.74%210.54M | 19.91%119.42M | -25.03%66.98M | -38.75%207.02M | 348.27%105.94M | 15.14%99.59M | -38.69%89.34M | -3.55%338.01M | 23.63M |
Income tax | 433.32%231.19M | 358.40%126.76M | 570.99%37.44M | 216.26%42.21M | -51.89%43.35M | 140.12%27.65M | -79.58%5.58M | -56.67%13.35M | 5.86%90.11M | 11.52M |
Net income | 30.02%212.81M | 7.03%83.79M | -12.80%81.98M | -67.41%24.76M | -33.98%163.67M | 546.13%78.29M | 58.87%94.01M | -33.87%75.99M | -6.57%247.9M | 12.12M |
Net income continuous Operations | 30.02%212.81M | 7.03%83.79M | -12.80%81.98M | -67.41%24.76M | -33.98%163.67M | 546.13%78.29M | 58.87%94.01M | -33.87%75.99M | -6.57%247.9M | --12.12M |
Minority interest income | -53.95%55.89M | -31.85%14.82M | -12.12%30.29M | -73.77%9.92M | 93.03%121.35M | 42.20%21.74M | 135.83%34.46M | 53.90%37.83M | -17.93%62.87M | 15.29M |
Net income attributable to the parent company | 270.81%156.92M | 21.98%68.97M | -13.19%51.69M | -61.12%14.84M | -77.13%42.32M | 1,881.41%56.54M | 33.63%59.54M | -57.75%38.17M | -1.96%185.04M | -3.17M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 270.81%156.92M | 21.98%68.97M | -13.19%51.69M | -61.12%14.84M | -77.13%42.32M | 1,881.41%56.54M | 33.63%59.54M | -57.75%38.17M | -1.96%185.04M | -3.17M |
Basic earnings per share | 283.33%0.23 | 21.74%0.1014 | -13.34%0.0761 | -66.67%0.02 | -77.78%0.06 | 1,879.46%0.0833 | 33.73%0.0878 | -54.91%0.06 | -3.57%0.27 | -0.0047 |
Diluted earnings per share | 283.33%0.23 | 21.74%0.1014 | -13.34%0.0761 | -66.67%0.02 | -77.78%0.06 | 1,879.46%0.0833 | 33.73%0.0878 | -54.91%0.06 | -3.57%0.27 | -0.0047 |
Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Currency Unit | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR | EUR |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- |